Pharmaceuticals, Biotechnology and Life Sciences
Biogen and Alkermes got approval from USFDA for Vumertiy, a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
Alkermes and Biogen said the FDA will check their novel oral fumarate in development for diroximel fumarate (BIIB098), for the treatment…
Alkermes has received a $50 million payment from Biogen after it reviewed the preliminary gastrointestinal tolerability data from the ongoing…
Alkermes will attempt to get new approval from the USFDA for its investigational drug for treating major depressive disorder (MDD).
Alkermes revealed positive results from a phase 4 clinical study of its schizophrenia injectable drug Aristada. Alkermes said on Monday…
The U.S. Food and Drug Administration (FDA) has approved Alkermes’s two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.
Alkermes, a global biopharmaceutical company developing medicines for the treatment of central nervous system…
Alkermes plcp has announced that the U.S. Food and Drug Administration (FDA) has approved Aristadatm (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.